Although Mounjaro and Zepbound have been headlining Lilly’s financial reports in recent years, the company’s roster of ...
Eli Lilly is set to report fourth-quarter earnings early Thursday, with analysts expecting rising sales and profit in the first full quarter with the company's weight-loss drugs no longer in shortage.
That’s how much Eli Lilly’s revenue grew in 2024, but it was still not as much as the company or investors expected, which had CEO David Ricks trying to assuage investors. Lilly on Tuesday ...
Real-time index price for S&P Smallcap 600 (IQY), along with buy or sell indicators, analysis, charts, historical performance, news and more ...
Hosted on MSN1mon
Drug-Trial Results Could Shake Up Pharma Stocks in 2025. Watch Eli Lilly, Pfizer, and More.Eli Lilly The world’s biggest pharmaceutical company by market value ... Novo said it would conduct another Phase 3 trial during the first half of 2025 to better determine optimal dosing.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results